抽象的
通过24微克(200微克)对24微克(200微克)对24微克的计量剂量气溶胶给予的短期保护作用和蛋白质醇的持续作用。(200微克)和12个哮喘的EIA阳性患者在双盲,安慰剂控制,三期交叉研究。在每个治疗日,患者被给予其中一种药物或安慰剂,并在给药后第二个和第八小时进行两次运动试验。使用标准程序,通过跑步机在受控的环境条件下进行锻炼。In the first test at 2 h a significant difference relative to placebo (p less than 0.001) at each incremental time after exercise (i.e. 5, 10, 15, 20, 30 min) was obtained with both formoterol and salbutamol, without any significant difference between formoterol and salbutamol. After the eighth hour test formoterol still protected against EIA in comparison to both salbutamol and placebo. The effect of salbutamol at this time was not different from placebo. No adverse effects were reported in any treatment group. Formoterol has a long duration of action in protecting against EIA that persisted for eight hours, removing the need to dose with beta 2-agonist before every exercise.